A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This is an observational, pilot, non-treatment study to evaluate and develop clinical variables for distinguishing female OAB subjects that have detrusor overactivity positive (DO+) nocturia from female OAB subjects that have detrusor overactivity negative (DO-) nocturia utilizing a sleep laboratory setting.

See also
Status	Clinical Trial	Phase
Completed	`NCT01029015` - Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects	Phase 4
Recruiting	`NCT00546208` - Unilateral Cutaneous Ureterostomy - Long Term Follow up	N/A
Recruiting	`NCT05786391` - Trendelenburg, Abdominal Insufflation and Time to Completion of Cystoscopy	N/A

NCT number	NCT01099345
Study type	Observational
Source	Astellas Pharma Inc
Contact
Status	Terminated
Phase	N/A
Start date	July 2010
Completion date	May 2012

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms